INTRODUCTION
============

Therapy-related acute myeloid leukemia (t-AML) caused by radioactive iodine (RAI) occurs in less than 2% of thyroid cancer patients and is associated with a poor therapeutic response and prognosis \[[@B1]-[@B3]\]. Many cases of t-AML have occurred in \>50-year-old patients after they received a cumulative radioiodine dose of more than 800 mCi, with intervals of less than 12 months between ^131^I therapies \[[@B1]-[@B3]\]. Over 90% patients with t-AML or therapy-related myelodysplastic syndrome (t-MDS) exhibit an abnormal karyotype with approximately 70% patients having an unbalanced chromosomal aberration and the remaining 30% having a balanced chromosomal translocation \[[@B4]\]. Inv(16)(p13.1q22) is found in approximately 5-8% of patients with *de novo* acute myeloid leukemia (AML), but it is rarely reported in patients with t-AML. In 20-30% of t-AML patients, the first manifestation is AML without a preceding myelodysplastic phase \[[@B4]\].

Here, we report the case of a 38-year-old woman who developed t-AML with inv(16)(p13.1q22). *CBFB-MYH11*, markedly increased eosinophils, and *K-ras* mutation were noted after treating her for thyroid cancer with a single low intensity dose of ^131^I.

CASE REPORT
===========

A 38-year-old woman was admitted to our hematology clinic with a 10-day history of dyspnea and dizziness. She was diagnosed with papillary thyroid cancer 15 months prior to the admission, and had received a single dose of 150 mCi ^131^I. The patient\'s condition remained stable thereafter on a suppressive dose of thyroid hormone. On physical examination, the patient appeared pale without other abnormalities. Peripheral blood analysis revealed hemoglobin level of 7.2 g/dL; platelet counts of 7,000×10^9^/L; and a white blood cell count of 47.39×10^9^/L with 60% blasts, 23% monocytes, and 4% eosinophils ([Fig. 1A](#F1){ref-type="fig"}). The bone marrow (BM) aspiration revealed 10% myeloblasts, 20.4% monoblasts/promonocytes, and 53.4% eosinophils ([Fig. 1B](#F1){ref-type="fig"}).

Immunophenotyping using flow cytometry revealed 2 populations of blast cells. One population showed positivity for CD45, CD34, myeloperoxidase (MPO), CD13, CD33, CD117, CD14, and HLA-DR, while the other population showed positivity for CD45, MPO, CD13, CD33, CD14, and HLA-DR. Blast cells were stained for MPO and α-naphthyl-butyrate esterase ([Fig. 1C and 1D](#F1){ref-type="fig"}). BM cytogenetic analysis showed inv(16)(p13.1q22) in 20 analyzed metaphases ([Fig. 1E](#F1){ref-type="fig"}). The result of fluorescence *in situ* hybridization (FISH) revealed that 89% of the nucleated cells had an abnormal break-apart signal pattern, that is, nuc ish(CBFB×2) (5\'CBFB-sep3\' CBFB×1)\[356/400\] (Vysis Inc., IL, USA; [Fig. 1F](#F1){ref-type="fig"}). In the molecular study, gene rearrangements such as *PML/RARa*, *AML1/ETO*, and *BCR/ABL*, and a mutation in the *FLT3* gene (ITD or D835Y) were negative. The *K-ras* mutation in codon 12 (G\>A transition, GGT→GAT) was detected by the pyrosequencing method, and this mutation induced an amino acid change of wild-type glycine (G) to aspartic acid (D) (TheraScreen NRAS/KRAS Pyro kit, QIAGEN, Hamburg, Germany). The mutant allele burden in BM mononuclear cells was 42% ([Fig. 2A](#F2){ref-type="fig"}). Based on the World Health Organization\'s (WHO) 2008 criteria, the condition was diagnosed as t-AML with inv(16)(p13.1q22); *CBFB-MYH11*.

Blasts in peripheral blood and BM decreased rapidly after induction chemotherapy with cytarabine (100 mg/m^2^ for 7 days) and idarubicin (12 mg/m^2^ for 3 days), and the *K-ras* mutation, and the inv(16) rearrangement disappeared ([Fig. 2B](#F2){ref-type="fig"}). The first consolidation therapy with cytarabine (100 mg/m^2^ twice a day (b.i.d.) for 4 days) and daunorubicin (45 mg/m^2^ for 3 days), and the second consolidation therapy with cytarabine (100 mg/m^2^ b.i.d. for 4 days) and idarubicin (12 mg/m^2^ for 3 days) were performed without serious complications. After the third consolidation therapy using high-dose cytarabine (3,000 mg/m^2^ b.i.d. for 3 days), the patient has continued to have thrombocytopenia without blast increase.

DISCUSSION
==========

RAI therapy has been the treatment of choice for toxic nodular goiter, Grave disease, and metastatic thyroid cancer. The National Thyroid Cancer Treatment Co-operative Group recently reported that RAI treatment in thyroid carcinoma had been administered in 62-75% of individuals in a cohort study \[[@B5]\]. Meta-analysis using 16,502 patients showed that the relative risk (RR) of second primary malignancy was increased in thyroid cancer patients treated with ^131^I (RR=1.19), and that the RR for the development of leukemia was increased by 2.5-fold in thyroid cancer patients treated with RAI \[[@B1]\].

Even though leukemia is a rare complication of ^131^I therapy in these patients, the possible carcinogenic effect of ^131^I is still a concern. Pochin described 4 cases of acute leukemia in 175 patients treated with ^131^I for thyroid cancer, observing a leukemia incidence of 2.3% \[[@B2]\]. One group reported a case that the latency period from exposure to the occurrence of acute leukemia was 14 months \[[@B6]\]. The patient described here had received only a single dose of 150 mCi, and she developed AML in a shorter latency period than that seen in other t-AML cases. Moreover, Roldán reported 2 cases of AML, that is, AML with maturation (M~2~, French-American-British (FAB) classification) and acute promyelocytic leukemia, after a single dose of 150 mCi in patients who were diagnosed with papillary thyroid carcinoma. The latency periods of these 2 patients were 2 and 5 years, respectively \[[@B7]\].

Another report by Anderson et al. focused on 48 patients who had a history of other primary disease such as breast cancer, lymphoma, or various other solid tumor and non-malignant disease, and were diagnosed with t-MDS/t-AML with inv(16). Ten of these patients (20.8%) received radiation therapy only, and inv(16) is more frequent in patients treated with only radiotherapy \[[@B8]\]. Patients with inv(16) exhibited a shorter latency period from the start of treatment for the primary tumor to the development of t-MDS/t-AML than did patients with other therapy-related diseases (median, 22 months; range, 8-533 months). Within the inv(16) subgroup, patients younger than 55 years of age had a longer survival period compared with patients older than 55 years of age \[[@B8]\]. However, Schroeder et al. had suggested that t-MDS/t-AML after RAI treatment was usually associated with an advanced disease stage, adverse chromosomal changes, a low response to induction chemotherapy, and a short overall survival even with the numerous treatment options \[[@B9]\].

Based on these findings, the patient presented here may be expected to have a poor outcome despite the presence of less severe risk factors such as inv(16) and young age. However, in the previous study, the t-AML with inv(16) (p13.1q22) or t(16;16)(p13.1;q22) was morphologically identical to its *de novo* counterpart \[[@B4]\], while in the current case, the patient revealed strikingly increased eosinophils (53.4%) compared with eosinophilia in *de novo* AML with inv(16) that ranged from 1% to 33% \[[@B10]\]. The eosinophils had characteristically coarse, purple-violet colored granules that were larger than those of normal eosinophils ([Fig. 1B](#F1){ref-type="fig"}). Importantly, Pulsoni et al. previously demonstrated that eosinophilia is a favorable prognostic factor and that the concomitant presence of both inv(16) and eosinophilia is associated with a significantly improved prognosis \[[@B11]\].

The common *Ras* gene mutation is a one base substitution in codon 12, 13, or 61 leading to constant activity of the Ras protein, which is caused by the guanosine triphosphate-bound status and can induce uncontrolled cell proliferation and escape from apoptosis \[[@B12]\]. The frequency of *K-ras* mutations at codon 12, 13, or 61 in AML patients has been reported to range from 3.5% to 13.3%. In a study by Valk et al., *K-ras* mutations in codon 12 were found in 7% of the patients with AML and inv(16) \[[@B13]\]. The *in vitro* data suggest that mutant *Ras* promotes a myeloid maturation defect with relative sparing of the monocyte-macrophage lineage. This may be consistent with the overrepresentation of *Ras* mutations in the acute myelomonocytic leukemia (M4)/acute monoblastic and monocytic leukemia (M5) FAB types \[[@B14]\].

Based on these observations, Gilliland proposes a two-hit theory for leukemogenesis in which AML arises from the collaboration between 2 classes of mutations \[[@B15]\]. Class I mutations confer a proliferative and/or survival advantage to cells (*BCR-ABL* fusion gene and oncogenic *Ras*), while Class II mutations impair hematopoietic differentiation and apoptosis (*CBFβ-MYH11* and *PML-RARα* fusion gene) \[[@B15]\]. The patient described here had both a K-ras mutation and inv(16) at the time of t-AML diagnosis, and these abnormalities were not detected after achieving complete remission. It can be presumed that these findings support the two-hit model of leukemogenesis, and that *K-ras* mutation and inv(16) correlate with leukemogenesis in this patient.

In conclusion, only a small proportion of thyroid cancer patients treated with radioiodine have developed leukemia, and different dose ranges and latent periods have been reported in various trials. The case presented here is a rare case of inv(16) in t-AML that developed after a single low-dose iodine therapy. Although the risk of leukemia after ^131^I exposure is hardly considered a contraindication to ^131^I therapy, hematological follow-up of patients admitted for ^131^I treatment is recommended.

![Morphologic and cytogenetic study. **(A)** Peripheral blood smear and **(B)** bone marrow aspirates show myeloblasts, immature monocyte precursors, and abnormal eosinophils. The eosinophil count is markedly increased (53.4%), and some eosinophils have basophilic granules (Wright Giemsa stain ×1,000). **(C)** Blasts are positive for myeloperoxidase (MPO). **(D)** The marrow monocytic component is stained by α-naphthyl-butyrate esterase. **(E)** The karyotype reveals 46,XX,inv (16)(p13.1q22)\[20\] (GTL banding, ×1,000). **(F)** FISH using a LSI CBFB Dual Color Break Apart Rearrangement Probe reveals separate red (5\' *CBFB* gene) and green (3\' *CBFB* gene) signals, resulting in distinct hybridization signals on the arm of the inverted chromosome 16, and these signals were expressed in more than 89% of the cells. The normal *CBFB* allele is seen as one fused red-green (yellow) signal.](kjh-47-225-g001){#F1}

![*K-ras* mutation by pyrosequencing. Pyrogram shows the mutation and mutated clones. The X axis means the base and the Y axis represents the intensity of fluorescent signal. Shaded regions represent *K-ras* codons 12 and 13. **(A)** Arrow shows the analytic results of substitutions in the second base of *K-ras* codon 12. The mutation GGT (Gly) to GAT (Asp) in codon 12 was detected by pyrosequencing. **(B)** After induction of chemotherapy, the *K-ras* mutation disappeared.](kjh-47-225-g002){#F2}
